Hodgkin’s lymphoma symptoms: Signs of the cancer you should know

HODGKIN ’S lymphoma is a form of cancer which develops in the lymphatic system - which is part of the immune system.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news

Related Links:

CONCLUSIONS: Absolute numbers of cases of HL at our centre have increased since the roll-out of antiretroviral therapy (ART) to the public sector. The recent change in policy to make ART available to all HIV-positive patients independent of CD4+ count suggests that patients will survive longer and are therefore at increased risk of developing HL. We anticipate that numbers of HL cases will increase or remain high in the coming years, and we need to prepare for this. PMID: 30004343 [PubMed - in process]
Source: South African Medical Journal - Category: African Health Tags: S Afr Med J Source Type: research
Conclusions: Taken together, this work demonstrated that miR-181b might have the ability to overcome chemo resistance of small cell lung cancer cells, and restoration of this miRNA may represent a potential therapeutic strategy for improving chemo sensitivity in small cell lung cancer. PMID: 30002690 [PubMed]
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
I read with interest the proposal of the European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma task force concerning B ratings based on absolute counts of CD4+CD26 − or CD4+CD7− lymphocytes, that is, B0,
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
The comments on blood class in erythrodermic cutaneous T-cell lymphoma (CTCL) from E. Vonderheid are received with interest by our European Organisation for Research and Treatment of Cancer (EORTC) group. First, it should be noted that our recent EORTC consensus statement defined blood class according to flow cytometry [1] and included all patients with mycosis fungoides (MF) and Sezary syndrome (SS). E. Vonderheid commented on blood class in erythrodermic MF/SS, and it must be recognised that blood involvement is much more frequent in erythrodermic CTCL than patch, plaque and tumour stage MF p  
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
ConclusionsOur findings are not consistent with a discernable effect of cellphone use patterns in Israel on incidence trends of brain, CNS and intracranial tumors.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Conclusions: TP53 mutations reduce responsiveness to crizotinib and worsen prognosis in ALK rearrangement NSCLC patients. PMID: 29997966 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
Condition:   Lymphoma Intervention:   Drug: Pembrolizumab Sponsor:   Abramson Cancer Center of the University of Pennsylvania Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions.   It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma.  In neuroblastoma, patients undergo a very aggress ive standard of care regimen that results in a high mortality rate.  Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Abstract The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10 years, achieved long-term survivals exceeding 1...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Health | Lymphoma